Kenya Medical Research Institute

What Kenya Medical Research Institute does

Kenya Medical Research Institute (KEMRI), founded in 1979 and headquartered in Nairobi, is the Kenyan government's premier medical research institution. It operates as a state-owned entity under the Ministry of Health, employing 501–1,000 staff, and conducts clinical trials, vaccine development, traditional herbal medicine research, and infectious disease studies. KEMRI has recently been elevated to strategic national institution status and serves as a key research partner in multi-country clinical trials across East and West Africa, including Phase III malaria-in-pregnancy trials (Mali, Burkina Faso, Kenya) and the €15.3 million ACT-CHIK chikungunya vaccine programme (Rwanda, Kenya, Nigeria, Senegal).

KEMRI's core research portfolio spans four major programmes: a Traditional Herbal Medicine Research Programme documenting 140+ medicinal plant species and developing six anti-cancer herbal drugs for pilot testing at Iten County Referral Hospital from July 2026; malaria-in-pregnancy clinical trials; the MV-CHIK chikungunya vaccine trial enrolling 940 participants; and the LEA-WH women's health research fellowship hosted in partnership with the U.S. National Academy of Medicine. The institute is also Kenya's principal research partner in the WHO and Medicines Patent Pool mRNA Technology Transfer Programme, supporting the country's $120M World Bank-backed BioVax facility targeting domestic vaccine production by 2027.

KEMRI does not operate on a commercial pricing model; it is funded through Kenyan government appropriations and international donor grants, with Kenya reportedly reliant on donor financing for over 80% of its vaccine needs. Its customer base is exclusively governmental — including the Kenya Ministry of Health, Kenya BioVax Institute, and county governments — and its outputs are disseminated through peer-reviewed publications, international health forums, and government-to-government technology transfer partnerships rather than commercial channels. The institute's strategic positioning has been strengthened by the government's 10-year Science, Research, and Innovation Master Plan, which aims to raise national research funding from 0.8% to 2% of GDP.

Name

Kenya Medical Research Institute

Legal name

Kenya Medical Research Institute

Website

https://kemri.go.ke

Company type

Private

Founded year

1979

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Kenya Medical Research Institute (KEMRI) is a government-owned national medical research institute in Nairobi conducting clinical trials, vaccine development, traditional herbal medicine research, and infectious disease studies to serve Kenya's public health system and international partners.

Ownership category

akta.pro rank

Product category

Medical Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511)

SIC

Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

akta.pro secondary industries

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF), Microbiology & Infectious Disease Testing (Trial Support) (HLAGAEAF)

Keywords

• Clinical trial research
• Vaccine development
• Infectious disease research
• Traditional herbal medicine
• Medical research

Headquarters

HQ city

Nairobi

HQ country

Kenya

HQ region

Africa

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Distribution channels3 records

Marketing channels3 records

Core offering

Kenya Medical Research Institute (KEMRI) is a government-owned medical research institution that conducts clinical trials, vaccine development studies, traditional herbal medicine research, and infectious disease research. Its portfolio includes Phase III clinical trials for anti-malaria drugs in pregnancy and the MV-CHIK chikungunya vaccine, research on medicinal plants (140+ documented species, six anti-cancer drug candidates), and training programs such as the LEA-WH women's health research fellowship. KEMRI serves as a key research partner in the WHO mRNA Technology Transfer Programme supporting vaccine manufacturing capacity building across Africa.

Product overview

Kenya Medical Research Institute (KEMRI) operates as a national medical research organisation providing research services rather than commercial products. Its portfolio consists primarily of clinical trial services and research programmes including traditional herbal medicine integration into healthcare, malaria vaccine trials in pregnancy, chikungunya vaccine clinical trials, and women's health research fellowships. KEMRI serves as a key research partner in the WHO mRNA Technology Transfer Programme supporting vaccine manufacturing capacity building in Africa.

Differentiator

Problem solved

Functional benefit

Products and services

• Traditional Herbal Medicine Research Programme KEMRI's research programme integrating traditional herbal medicine into Kenya's mainstream healthcare system, involving documentation of over 140 medicinal plant species, prioritisation of six for cancer research, and development of six potential anti-cancer herbal drug candidates scheduled for pilot testing at Iten County Referral Hospital. The programme serves Kenyan county governments and the national health system in formalising traditional medicine evidence by the 2028 target.
• Malaria in Pregnancy Clinical Trials Phase III clinical trials testing the safety and efficacy of two anti-malaria drugs in pregnant women during the first trimester, conducted in partnership with European institutions across Mali, Burkina Faso, and Kenya. The service generates regulatory evidence to expand treatment options and inform maternal malaria clinical guidelines.
• Chikungunya Vaccine Clinical Trials (MV-CHIK) Clinical trials for the MV-CHIK chikungunya vaccine as part of the ACT-CHIK project, a €15.3 million four-year research initiative funded by the Global Health EDCTP3 Joint Undertaking, with technology transfer preparation for local vaccine manufacturing to be hosted at Institut Pasteur de Dakar. The service enrolls 940 participants across age groups in Rwanda, Kenya, Nigeria, and Senegal.
• Women's Health Research Program (LEA-WH) Three-year fellowship programme hosted by KEMRI and led by the National Academy of Medicine, training up to 20 mid-career women's health researchers per year across Africa through in-person and virtual convenings with mentorship and professional development support. The programme builds senior research capacity in women's health across the continent.

Quantifiable outcome

• Phase III clinical trial for malaria in pregnancy expanded treatment options for pregnant women in first trimester across Mali, Burkina Faso, and Kenya
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Institut PasteurcoreStrategic or Co-development Partner · 8 June 2026ACT-CHIK project: €15.3 million four-year research funded by Global Health EDCTP3 Joint Undertaking to advance MV-CHIK chikungunya vaccine Phase Ib/III trials across Rwanda, Kenya, Nigeria, and Senegal. KEMRI participating in trial enrollment of 940 participants with technology transfer preparation for local vaccine manufacturing.
• Europe-Africa Research Partnership (Clinical Trial Consortium)coreStrategic or Co-development Partner · 24 April 2026Phase III clinical trial testing anti-malaria drugs safety and efficacy in pregnant women during first trimester. KEMRI conducting trials in Mali, Burkina Faso, and Kenya to expand treatment options and inform guidelines.
• Elgeyo-Marakwet County GovernmentcoreStrategic or Co-development Partner · 21 March 2026Partnership to integrate traditional herbal medicine into Kenya's mainstream healthcare system. KEMRI researchers documented 140+ medicinal plant species, developed six potential anti-cancer herbal drugs for pilot testing at Iten County Referral Hospital.
• Cardiff UniversityminorStrategic or Co-development Partner · 20 March 2026Partnership on SunPad project - a low-cost, self-sanitising, reusable menstrual product. KEMRI assessing manufacturing capabilities, supply chains, and user demand for the solar-powered menstrual product.
• STADA KenyaminorChannel Partner/ Reseller/ Distributor · 20 March 2026Local manufacturer partnered with Cardiff University and KEMRI for SunPad menstrual product production and distribution in Kenya.
• World Health Organization (WHO)coreStrategic or Co-development Partner · 25 February 2026Kenya selected as one of six African countries to join WHO and Medicines Patent Pool mRNA Technology Transfer Programme. KEMRI serves as key research partner for comprehensive end-to-end vaccine production training through Kenya BioVax Institute.
• Medicines Patent PoolcoreStrategic or Co-development Partner · 25 February 2026Joint programme with WHO to build vaccine manufacturing capacity in lower-income countries. KEMRI is key research partner in mRNA technology transfer to enable domestic vaccine production.
• National Academy of Medicine (NAM)coreStrategic or Co-development Partner · 22 October 2025LEA-WH program: Three-year fellowship targeting mid-career women's health researchers across Africa. KEMRI hosts the program training up to 20 scholars per year through in-person and virtual convenings with mentorship and professional development.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• PATH Center for Vaccine Innovation and Access: PATH's vaccine program partners with African research institutions to advance low-cost vaccines against diseases of public health importance. A functional peer in vaccine trial implementation and tech-transfer partnerships across Africa.
• South African Medical Research Council (SAMRC): South Africa's national medical research council funds and conducts health research across the disease spectrum. As Africa's largest publicly funded health research entity with clinical trial infrastructure, it is the most direct organizational and mandate peer to KEMRI.
• International Vaccine Institute (IVI): Based in Seoul, IVI is a globally focused product development partnership advancing vaccines for developing-country diseases. Comparable as a vaccine clinical development partner working across Africa, including the malaria and chikungunya indications relevant to KEMRI.

Emerging players

• Medicines for Malaria Venture (MMV): MMV is the leading product development partnership for malaria therapeutics and is referenced in the same Phase III malaria-in-pregnancy trial ecosystem as KEMRI. Direct trial-sponsor overlap with KEMRI's pregnancy-malaria program.

Direct peers

• Institut Pasteur de Dakar: Senegal-based Institut Pasteur is the named technology-transfer recipient in the ACT-CHIK project and an African vaccine development hub. KEMRI is explicitly its trial collaborator, making it a direct functional peer in vaccine clinical research and emerging manufacturing.
• National Institute for Communicable Diseases (South Africa): South Africa's NICD conducts surveillance, clinical trials, and outbreak response for infectious diseases including malaria and arboviruses. Overlaps directly with KEMRI's Phase III malaria and chikungunya vaccine trial work across Africa.

Regional players

• Mwanza Intervention Trials Unit / Tanzania National Institute for Medical Research: Tanzania's national medical research institute runs clinical trials in infectious diseases, particularly malaria and HIV. Comparable role within East Africa and a likely trial-partner candidate for sponsors working across the region with KEMRI.
• Uganda Virus Research Institute / MRC/UVRI & LSHTM Uganda Research Unit: Uganda's flagship virology and clinical trials center runs Phase I–III trials on vaccines and therapeutics for HIV, Ebola, and emerging pathogens. Directly comparable to KEMRI in terms of portfolio scope and East African trial footprint.
• Noguchi Memorial Institute for Medical Research (University of Ghana): Ghana's leading biomedical research institute conducts clinical trials and infectious disease research as a national public health laboratory. Operates a parallel continental mandate to KEMRI and serves overlapping African clinical trial sponsors.

Others

• Coalition for Epidemic Preparedness Innovations (CEPI): CEPI funds and coordinates vaccine R&D against emerging epidemic threats, including chikungunya and other pathogens relevant to KEMRI's pipeline. Comparable as a funding and trial-coordination counterpart rather than a direct trial operator.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/KEMRI_Kenya

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kenya Medical Research Institute